NDRA · ENDRA Life Sciences Inc.
$6.06
+0.18 (+3.06%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, management believes that without the closing of the Merger, given our current cash position and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about our ability to continue as a going concern after the date that is one year from the date that these financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$9.06M
Shares
1.50M
Volume · Oct 2
39.79K
Avg daily vol (3M)
36.4K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.06
Open$5.96
Day$5.92–6.11
52W close$3.26–8.12
Avg vol 30d50K
Short int31K · 2.1% float · 1.0d
Short vol33%
Last earningsMar 31, 2025
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
call held Aug 23, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$5.92M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+245.2%
Year over year · more shares
Price change (1Y)
+4.8%
Trailing year
Short interest
2.1%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+27%
above
Price vs 50-day avg
+17%
above
RSI (14)
56
neutral
MACD trend
Negative
52-week position
58%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+7%
trailing
6-month return
+17%
trailing
YTD return
+34%
this year
Relative strength
+5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Accumulating
+25% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.09% of float · ▼ -0.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
10 holders — mid 3-yr range
Squeeze score
47
elevated · 0–100
Fundamentals
EPS growth
+84%
Y/Y
Free cash flow
$-5.2M
Balance sheet
$3.2M
net cash
Quant / Vol
risk profile
Volatility
111%
annualized · 1-yr
Max drawdown
−60%
past year
ATR
8.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+27%
Bullish
Price vs 50-day avg
+17%
Bullish
RSI (14)
56
Neutral
MACD trend
Negative
Bearish
52-week position
58%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Accumulating
+25% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.09% of float · ▼ -0.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
10 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $6 · 58%
Range high $8
vs 200-day avg +27%
vs 50-day avg +17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NDRA
this stock
ENDRA Life Sciences Inc.
|
$9.06M | +33.8% | -31.8% | — | 2.1% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +13.0% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$150.37B | -6.5% | +8.5% | 37.9 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +79.1% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +23.3% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NDRA | +0.3% | +6.7% | +16.8% | +1.7% | +33.8% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +0.6% | +7.2% | +4.6% | +0.8% | +20.9% |